{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T06:37:35Z","timestamp":1782283055093,"version":"3.54.5"},"reference-count":40,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007519","name":"Nephcure","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007519","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020652","name":"Nephrotic Syndrome Study Network","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020652","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019531","name":"Apellis Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019531","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031531","name":"Travere Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031531","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["U2CTR002818"],"award-info":[{"award-number":["U2CTR002818"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016650","name":"Rare Diseases Clinical Research Network","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016650","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009268","name":"Alport Syndrome Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009268","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007270","name":"University of Michigan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007270","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019452","name":"Halpin Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019452","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.ekir.2025.04.055","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T19:27:49Z","timestamp":1746559669000},"page":"2732-2740","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Serum Syndecan-1 is Associated With Kidney and Cardiovascular Outcomes in Idiopathic Nephrotic Syndrome"],"prefix":"10.1016","volume":"10","author":[{"given":"Colin","family":"Bauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arshia","family":"Anand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Sethna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Troost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarak","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imtiazul","family":"Islam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Fetsko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie A.","family":"Dougherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William E.","family":"Smoyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Cara-Fuentes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2025.04.055_bib1","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S0140-6736(23)01051-6","article-title":"Childhood nephrotic syndrome","volume":"402","author":"Vivarelli","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2025.04.055_bib2","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ekir.2020.10.033","article-title":"A national registry study of patient and renal survival in adult nephrotic syndrome","volume":"6","author":"Kolb","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2025.04.055_bib3","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1681\/ASN.2020111583","article-title":"Primary nephrotic syndrome and risks of ESKD, cardiovascular events, and death: the Kaiser Permanente nephrotic syndrome study","volume":"32","author":"Go","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.04.055_bib4","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.012143","article-title":"Prevalence of cardiovascular disease risk factors in childhood glomerular diseases","volume":"8","author":"Ashoor","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ekir.2025.04.055_bib5","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ekir.2019.12.015","article-title":"Prediction of short- and long-term outcomes in childhood nephrotic syndrome","volume":"5","author":"Carter","year":"2020","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2025.04.055_bib6","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s00467-013-2525-5","article-title":"Venous thromboembolism in pediatric nephrotic syndrome","volume":"29","author":"Kerlin","year":"2014","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ekir.2025.04.055_bib7","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1007\/s00467-020-04773-3","article-title":"Adult survivors of idiopathic childhood onset nephrotic syndrome","volume":"36","author":"Marchel","year":"2021","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ekir.2025.04.055_bib8","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41572-020-0196-7","article-title":"Podocytopathies","volume":"6","author":"Kopp","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.ekir.2025.04.055_bib9","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1681\/ASN.2021060794","article-title":"Discovery of autoantibodies targeting nephrin in minimal change disease supports a novel autoimmune etiology","volume":"33","author":"Watts","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.04.055_bib10","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa2314471","article-title":"Autoantibodies targeting nephrin in Podocytopathies","volume":"391","author":"Hengel","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.04.055_bib11","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1681\/ASN.2019080825","article-title":"Ultrastructural characterization of proteinuric patients predicts clinical outcomes","volume":"31","author":"Royal","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.04.055_bib12","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.ekir.2021.11.037","article-title":"Minimal change disease is associated with endothelial glycocalyx degradation and endothelial activation","volume":"7","author":"Bauer","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2025.04.055_bib13","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1002\/path.3964","article-title":"Endothelial glycocalyx dysfunction in disease: albuminuria and increased microvascular permeability","volume":"226","author":"Salmon","year":"2012","journal-title":"J Pathol"},{"key":"10.1016\/j.ekir.2025.04.055_bib14","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13613-019-0575-y","article-title":"Association of endothelial and glycocalyx injury biomarkers with fluid administration, development of acute kidney injury, and 90-day mortality: data from the FINNAKI observational study","volume":"9","author":"Inkinen","year":"2019","journal-title":"Ann Intensive Care"},{"key":"10.1016\/j.ekir.2025.04.055_bib15","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.amjcard.2022.04.036","article-title":"Usefulness of serum biomarkers of endothelial glycocalyx damage in prognosis of decompensated patients with heart failure with reduced ejection fraction","volume":"176","author":"Kim","year":"2022","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ekir.2025.04.055_bib16","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.2337\/diabetes.55.04.06.db05-1619","article-title":"Endothelial glycocalyx damage coincides with microalbuminuria in type 1 diabetes","volume":"55","author":"Nieuwdorp","year":"2006","journal-title":"Diabetes"},{"key":"10.1016\/j.ekir.2025.04.055_bib17","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1681\/ASN.2005080834","article-title":"Endothelial dysfunction contributes to renal function-associated cardiovascular mortality in a population with mild renal insufficiency: the Hoorn study","volume":"17","author":"Stam","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.04.055_bib18","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1161\/CIRCULATIONAHA.110.940932","article-title":"Endothelial dysfunction and subsequent decline in glomerular filtration rate in hypertensive patients","volume":"122","author":"Perticone","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2025.04.055_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.573557","article-title":"Glomerular endothelial cells as instigators of glomerular sclerotic diseases","volume":"11","author":"Sol","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ekir.2025.04.055_bib20","doi-asserted-by":"crossref","first-page":"622","DOI":"10.5551\/jat.56424","article-title":"Relationship between endothelial dysfunction and prevalence of chronic kidney disease: the circulatory risk in communities study (CIRCS)","volume":"28","author":"Li","year":"2021","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.ekir.2025.04.055_bib21","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1161\/CIRCRESAHA.123.321752","article-title":"Endothelial cell dysfunction and increased cardiovascular risk in patients with chronic kidney disease","volume":"132","author":"Baaten","year":"2023","journal-title":"Circ Res"},{"key":"10.1016\/j.ekir.2025.04.055_bib22","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/ki.2012.428","article-title":"Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach","volume":"83","author":"Gadegbeku","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.04.055_bib23","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s00467-022-05739-3","article-title":"IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome","volume":"38","author":"Trautmann","year":"2023","journal-title":"Pediatr Nephrol"},{"issue":"6","key":"10.1016\/j.ekir.2025.04.055_bib24","first-page":"140","article-title":"Subcommittee on screening and management of high blood pressure in children. Clinical practice guideline for screening and management of high blood pressure in children and adolescents","volume":"140","author":"Flynn","year":"2017","journal-title":"Pediatrics"},{"issue":"3","key":"10.1016\/j.ekir.2025.04.055_bib25","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.jacl.2011.03.453","article-title":"Pediatric aspects of familial hypercholesterolemias: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia","volume":"5","author":"Daniels","year":"2011","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.ekir.2025.04.055_bib26","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s00467-008-1029-1","article-title":"Atherosclerosis risk factors in young patients formerly treated for idiopathic nephrotic syndrome","volume":"24","author":"Kniazewska","year":"2009","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ekir.2025.04.055_bib27","doi-asserted-by":"crossref","DOI":"10.1177\/14791641241278362","article-title":"Association of serum syndecan-1 concentrations with albuminuria in type 2 diabetes","volume":"21","author":"Kakutani","year":"2024","journal-title":"Diab Vasc Dis Res"},{"key":"10.1016\/j.ekir.2025.04.055_bib28","doi-asserted-by":"crossref","DOI":"10.1177\/10760296211010256","article-title":"The association of Syndecan-1, Hypercoagulable State and thrombosis and in patients with nephrotic syndrome","volume":"27","author":"Chen","year":"2021","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.ekir.2025.04.055_bib29","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.atherosclerosis.2014.03.016","article-title":"Damage of the endothelial glycocalyx in chronic kidney disease","volume":"234","author":"Padberg","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ekir.2025.04.055_bib30","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c4986","article-title":"Chronic kidney disease and risk of major cardiovascular disease and non-vascular mortality: prospective population based cohort study","volume":"341","author":"Di Angelantonio","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.ekir.2025.04.055_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0260350","article-title":"Serum syndecan-1 concentration in hospitalized patients with heart failure may predict readmission-free survival","volume":"16","author":"Kitagawa","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.ekir.2025.04.055_bib32","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1253\/circj.CJ-14-1195","article-title":"Syndecan-1 in acute decompensated heart failure--association with renal function and mortality","volume":"79","author":"Neves","year":"2015","journal-title":"Circ J"},{"key":"10.1016\/j.ekir.2025.04.055_bib33","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.2215\/CJN.13121215","article-title":"Inflammation and progression of CKD: the CRIC study","volume":"11","author":"Amdur","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.04.055_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2023.109273","article-title":"A spectrum of novel anti-vascular endothelial cells autoantibodies in idiopathic nephrotic syndrome patients","volume":"249","author":"Ye","year":"2023","journal-title":"Clin Immunol"},{"key":"10.1016\/j.ekir.2025.04.055_bib35","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.atherosclerosis.2014.01.055","article-title":"Endothelial dysfuntion in children with idiopathic nephrotic syndrome","volume":"233","author":"Sharma","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ekir.2025.04.055_bib36","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1159\/000110088","article-title":"Markers of endothelial dysfunction in children with idiopathic nephrotic syndrome","volume":"28","author":"Tkaczyk","year":"2008","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.ekir.2025.04.055_bib37","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1007\/s00467-024-06301-z","article-title":"Longitudinal analysis of blood pressure and lipids in childhood nephrotic syndrome","volume":"39","author":"Carboni","year":"2024","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ekir.2025.04.055_bib38","first-page":"3236","article-title":"Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice","volume":"119","author":"Stanford","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ekir.2025.04.055_bib39","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1194\/jlr.P800025-JLR200","article-title":"Partial recovery of the endothelial glycocalyx upon rosuvastatin therapy in patients with heterozygous familial hypercholesterolemia","volume":"50","author":"Meuwese","year":"2009","journal-title":"J Lipid Res"},{"key":"10.1016\/j.ekir.2025.04.055_bib40","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.3390\/jcm8091320","article-title":"Factors enhancing serum Syndecan-1 concentrations: a large-scale comprehensive medical examination","volume":"8","author":"Oda","year":"2019","journal-title":"J Clin Med"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024925002803?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024925002803?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T18:50:31Z","timestamp":1762627831000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024925002803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2468024925002803"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2025.04.055","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum Syndecan-1 is Associated With Kidney and Cardiovascular Outcomes in Idiopathic Nephrotic Syndrome","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2025.04.055","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}